

CLAIMS

1. Angiogenesis inhibiting molecule, which is selected from the group consisting of antibody H33, produced by
5 hybridoma 13H33 as deposited on 22 October 2003 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under the deposit accession number **DSM ACC2622**, fragments and derivatives thereof, for use as a medicament.

2. Angiogenesis inhibiting molecule as claimed in
10 claim 1 for use in the treatment or diagnosis of cancer.

3. Angiogenesis inhibiting molecule as claimed in claim 2 for use in the treatment or diagnosis of solid tumors.

4. Angiogenesis inhibiting molecule as claimed in any one of the claims 1-3, wherein the molecule is a fragment of
15 H33 selected from Fab fragments, Fv fragments, single domain antigen binding fragments, scFv and aggregates thereof, V_{HH} S.

5. Angiogenesis inhibiting molecules as claimed in any one of the claims 1-3, wherein the derivative of antibody H33 is a human monoclonal antibody having the same specificity as
20 H33.

6. Angiogenesis inhibiting molecule as claimed in claim 5, wherein the human monoclonal antibody is produced in transgenic mice.

7. Angiogenesis inhibiting molecule as claimed in any
25 one of the claims 1-3, wherein the molecule is a derivative selected from recombinant antibodies having the same specificity as antibody H33, humanized antibodies based on antibody H33 and chimeric antibodies based on antibody H33.

8. Use of angiogenesis inhibiting molecule as claimed
30 in any one of the claims 1-7 for the preparation of a therapeutical or diagnostic composition for the treatment of cancer.

9. Use of angiogenesis inhibiting molecule as claimed

in any one of the claims 1-7 for the preparation of a
therapeutical or diagnostic composition for the treatment of
solid tumors.

10. Therapeutical composition for the treatment of
5 cancer, in particular for the treatment of solid tumors,
comprising a therapeutically effective amount of one or more
of the angiogenesis inhibiting molecules as claimed in any one
of the claims 1-7 and an excipient, carrier or diluent.

11. Diagnostic composition for the diagnosis of
10 cancer, in particular for diagnosing solid tumors, comprising
a diagnostically effective amount of one or more of the
angiogenesis inhibiting molecules as claimed in any one of the
claims 1-7 and an excipient, carrier or diluent.

12. Use of antibody H33, produced by hybridoma 13H33
15 as deposited on 22 October 2003 with the Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH under the deposit
accession number **DSM ACC2622** for the preparation of a
pharmaceutical composition for the treatment or diagnosis of
solid tumors.

20 13. Therapeutical composition for the treatment of
cancer, in particular for the treatment of solid tumors,
comprising a therapeutically effective amount of antibody H33,
produced by hybridoma 13H33 as deposited on 22 October 2003
with the Deutsche Sammlung von Mikroorganismen und
25 Zellkulturen GmbH under the deposit accession number **DSM**
ACC2622, and an excipient, carrier or diluent.

14. Diagnostic composition for the diagnosis of
cancer, in particular for detecting solid tumors in the human
or animal body, comprising a diagnostically effective amount
30 of antibody H33, produced by hybridoma 13H33 as deposited on
22 October 2003 with the Deutsche Sammlung von Mikroorganismen
und Zellkulturen GmbH under the deposit accession number **DSM**
ACC2622, fragments or derivatives thereof and an excipient,

carrier or diluent.

15. Fragment of antibody H33 as produced by hybridoma 13H33 as deposited on 22 October 2003 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under the
5 deposit accession number **DSM ACC2622**, having the specificity of H33.

16. Fragment as claimed in claim 15 selected from Fab fragments, Fv fragments, single domain antigen binding fragments, scFv and aggregates thereof, $V_{HH}S$.

10 17. Derivative of antibody H33 as produced by hybridoma 13H33 as deposited on 22 October 2003 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH under the deposit accession number **DSM ACC2622**, having the specificity of H33.

15 18. Derivative as claimed in claim 17, which is a human monoclonal antibody having the same specificity as H33.

19. Derivative as claimed in claim 18, wherein the human monoclonal antibody is produced in transgenic mice.

20 20. Derivative as claimed in claim 17, which is selected from recombinant antibodies having the same specificity as antibody H33, humanized antibodies based on antibody H33 and chimeric antibodies based on antibody H33.

21. Fragment or derivative of monoclonal antibody H33 as claimed in any one of the claims 15-20 for use as a
25 medicament.

22. Fragment or derivative of monoclonal antibody H33 as claimed in any one of the claims 15-20 for use in the treatment or diagnosis of cancer.

23. Fragment or derivative of monoclonal antibody H33
30 as claimed in any one of the claims 15-20 for use in the treatment or diagnosis of solid tumors.

24. Use of a fragment or derivative of antibody H33 as claimed in any one of the claims 15-20 for the preparation of

a pharmaceutical composition for the treatment or diagnosis of cancer.

25. Use of a fragment or derivative of antibody H33 as claimed in any one of the claims 15-20 for the preparation of
5 a pharmaceutical composition for the treatment or diagnosis of solid tumors.